{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:55:25Z","timestamp":1790985325367,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["NO1 MH90001"],"award-info":[{"award-number":["NO1 MH90001"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.schres.2008.09.031","type":"journal-article","created":{"date-parts":[[2008,11,11]],"date-time":"2008-11-11T02:52:08Z","timestamp":1226371928000},"page":"22-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Does switching to a new antipsychotic improve outcomes?"],"prefix":"10.1016","volume":"107","author":[{"given":"Robert A","family":"Rosenheck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Covell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Essock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin","family":"Swartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Stroup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"McEvoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2008.09.031_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","article-title":"A depression rating scale for schizophrenics","volume":"3","author":"Addington","year":"1996","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.schres.2008.09.031_bib2","first-page":"222","article-title":"A rating scale for drug induced akathisia","volume":"131","author":"Barnes","year":"1989","journal-title":"British journal of psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2008.09.031_bib3","first-page":"30","article-title":"Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another","volume":"56","author":"Brown","year":"1995","journal-title":"Journal of Clinical Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2008.09.031_bib4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/schbul\/16.1.57","article-title":"Diagnosis of alcohol use disorders in schizophrenia","volume":"16","author":"Drake","year":"1990","journal-title":"Schizophrenia Bulletin"},{"issue":"12","key":"10.1016\/j.schres.2008.09.031_bib5","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1176\/ajp.2006.163.12.2090","article-title":"Effectiveness of switching antipsychotic medications","volume":"163","author":"Essock","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.schres.2008.09.031_bib6","series-title":"Structured Clinical Interview for Axes I and II DSM IV Disorders \u2013 Patient Edition (SCID-I\/P)","author":"First","year":"1996"},{"issue":"10","key":"10.1016\/j.schres.2008.09.031_bib7","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.4088\/JCP.v64n1017","article-title":"Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic","volume":"64","author":"Fleischhacker","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.schres.2008.09.031_bib8","series-title":"ECDEU Assessment Manual for Psychopharamcology","article-title":"Abnormal involuntary movements","author":"Guy","year":"1976"},{"key":"10.1016\/j.schres.2008.09.031_bib9","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","article-title":"The quality of life scale: an instrument for rating the schizophrenic deficit syndrome","volume":"10","author":"Heinrichs","year":"1984","journal-title":"Schizophrenia Bulletin"},{"issue":"5","key":"10.1016\/j.schres.2008.09.031_bib11","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1377\/hlthaff.22.5.84","article-title":"Managing psychotropic drug costs: will formularies work","volume":"22","author":"Huskamp","year":"2003","journal-title":"Health Affairs"},{"key":"10.1016\/j.schres.2008.09.031_bib12","series-title":"Crossing the Quality Chasm: A New Health System for the 21st Century","author":"Institute of Medicine, Committee on Quality of Health Care in America","year":"2001"},{"issue":"2","key":"10.1016\/j.schres.2008.09.031_bib13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4088\/JCP.v68n0206","article-title":"Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine","volume":"68","author":"Kane","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.schres.2008.09.031_bib14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.schres.2008.09.031_bib15","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","volume":"64","author":"Keefe","year":"2007","journal-title":"Archives of general psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2008.09.031_bib16","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hup.723","article-title":"Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone","volume":"20","author":"Lamo","year":"2005","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"key":"10.1016\/j.schres.2008.09.031_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0149-7189(88)90033-X","article-title":"A quality of life interview for the chronically mentally ill","volume":"11","author":"Lehman","year":"1988","journal-title":"Evaluation and Program Planning."},{"issue":"12","key":"10.1016\/j.schres.2008.09.031_bib18","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"for the CATIE investigators, 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: primary efficacy and safety outcomes of the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial","volume":"353","author":"Lieberman","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.schres.2008.09.031_bib20","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.schres.2008.09.031_bib21","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"issue":"9","key":"10.1016\/j.schres.2008.09.031_bib22","doi-asserted-by":"crossref","first-page":"574","DOI":"10.4088\/JCP.v60n0902","article-title":"Antidepressant medication change in clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors","volume":"60","author":"Nurnberg","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.schres.2008.09.031_bib23","doi-asserted-by":"crossref","unstructured":"Remington, G., Chue, P., Stip, E., Kopala, L., Girard, T. and Christensen, B., 2005. The crossover approach to switching antipsychotics: what is the evidence. Schizophrenia Research 76 (203) 267-272.","DOI":"10.1016\/j.schres.2005.01.009"},{"issue":"12","key":"10.1016\/j.schres.2008.09.031_bib24","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1176\/ajp.2006.163.12.2080","article-title":"Cost-effectiveness of second generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia","volume":"163","author":"Rosenheck","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2008.09.031_bib25","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.4088\/JCP.v67n1203","article-title":"Switching antidepressants after a first selective serotonin reuptake inhibitor in Major depressive disorder: a systematic review","volume":"67","author":"Ruhe","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2008.09.031_bib26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1176\/ajp.2007.164.2.201","article-title":"STAR\u204eD What have we learned","volume":"164","author":"Rush","year":"2007","journal-title":"American Journal of Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2008.09.031_bib27","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/00005650-200011000-00008","article-title":"Reliability and validity of the SF-12 health survey among people with severe mental illness","volume":"38","author":"Salyers","year":"2000","journal-title":"Medical Care"},{"issue":"Suppl 212","key":"10.1016\/j.schres.2008.09.031_bib28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","author":"Simpson","year":"1970","journal-title":"Acta Psychiat Scand"},{"issue":"23","key":"10.1016\/j.schres.2008.09.031_bib29","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1001\/jama.286.23.3003","article-title":"Choosing a first-line antidepressant. Equal on average does not mean equal for everyone","volume":"286","author":"Simon","year":"2001","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.schres.2008.09.031_bib30","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1525-1497.2005.0232.x","article-title":"Mora M. Principles for evidence-based drug formulary policy","volume":"20","author":"Simon","year":"2005","journal-title":"Journal of General Internal Medicine"},{"issue":"1","key":"10.1016\/j.schres.2008.09.031_bib31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","article-title":"The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development","volume":"29","author":"Stroup","year":"2003","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.schres.2008.09.031_bib32","doi-asserted-by":"crossref","unstructured":"Swartz, M.S., Wagner, H.R., Swanson, J.W., Stroup, T.S., McEvoy, J.P., Reimherr, F., Miller, D.D., McGee, M., Khan, A., Canive, J.M., Davis, S.M., Hsiao, J.K., Lieberman, J.A., 2008. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophrenia Research 100 (1\u20133), 39\u201352.","DOI":"10.1016\/j.schres.2007.11.034"},{"issue":"8","key":"10.1016\/j.schres.2008.09.031_bib34","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.4088\/JCP.v65n0808","article-title":"Early clinical experience with risperidone long-acting injection: a prospective, 6-mnth follow-up of 100 patients","volume":"65","author":"Taylor","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2008.09.031_bib35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4088\/JCP.v58n0103","article-title":"Fluoxetine treatment of patients who failed initial treatment with sertraline","volume":"58","author":"Thase","year":"1997","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2008.09.031_bib36","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/0269881105056668","article-title":"Switching antipsychotics: an updated review with a focus on quetiapine","volume":"20","author":"Weiden","year":"2006","journal-title":"Journal of Psychopharmacology"},{"issue":"2","key":"10.1016\/j.schres.2008.09.031_bib37","first-page":"67","article-title":"Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline","volume":"57","author":"Zarate","year":"1996","journal-title":"Journal of Clinical Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996408004477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996408004477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:22:21Z","timestamp":1760296941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996408004477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S0920996408004477"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2008.09.031","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does switching to a new antipsychotic improve outcomes?","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2008.09.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}